Cytosorbents Crp (CTSO) - Total Assets
Based on the latest financial reports, Cytosorbents Crp (CTSO) holds total assets worth $37.96 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cytosorbents Crp - Total Assets Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's total assets have evolved over time, based on quarterly financial data. Also see Cytosorbents Crp (CTSO) total market value for the company's overall valuation and market capitalisation.
Cytosorbents Crp - Asset Composition Analysis
Current Asset Composition (December 2025)
Cytosorbents Crp's total assets of $37.96 Million consist of 46.7% current assets and 53.3% non-current assets. Review CTSO total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.1% |
| Accounts Receivable | $7.55 Million | 17.1% |
| Inventory | $5.28 Million | 12.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.23 Million | 7.3% |
| Goodwill | $3.23 Million | 7.3% |
Asset Composition Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Cytosorbents Crp stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytosorbents Crp's current assets represent 46.7% of total assets in 2025, an increase from 33.3% in 2004.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2025, down from 33.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 17.1% of total assets.
Cytosorbents Crp Competitors by Total Assets
Key competitors of Cytosorbents Crp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Cytosorbents Crp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 2.34 | 6.57 |
| Quick Ratio | 0.50 | 1.96 | 6.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.29 Million | $13.14 Million | $61.68 Million |
Cytosorbents Crp - Advanced Valuation Insights
This section examines the relationship between Cytosorbents Crp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.43 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | -6.7% |
| Total Assets | $44.18 Million |
| Market Capitalization | $18.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cytosorbents Crp's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cytosorbents Crp's assets decreased by 6.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cytosorbents Crp (2004–2025)
The table below shows the annual total assets of Cytosorbents Crp from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $44.18 Million | -6.73% |
| 2024-12-31 | $47.37 Million | -11.06% |
| 2023-12-31 | $53.26 Million | -15.77% |
| 2022-12-31 | $63.23 Million | -29.37% |
| 2021-12-31 | $89.52 Million | -0.48% |
| 2020-12-31 | $89.95 Million | +228.49% |
| 2019-12-31 | $27.38 Million | -16.38% |
| 2018-12-31 | $32.75 Million | +35.86% |
| 2017-12-31 | $24.10 Million | +148.65% |
| 2016-12-31 | $9.69 Million | -13.87% |
| 2015-12-31 | $11.25 Million | +32.89% |
| 2014-12-31 | $8.47 Million | +109.33% |
| 2013-12-31 | $4.05 Million | +21.15% |
| 2012-12-31 | $3.34 Million | +57.33% |
| 2011-12-31 | $2.12 Million | +17.14% |
| 2010-12-31 | $1.81 Million | -19.06% |
| 2009-12-31 | $2.24 Million | -33.91% |
| 2008-12-31 | $3.39 Million | +322.04% |
| 2007-12-31 | $802.57K | -76.70% |
| 2006-12-31 | $3.45 Million | +17991.84% |
| 2005-12-31 | $19.04K | -36.53% |
| 2004-12-31 | $30.00K | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more